JW
Therapeutic Areas
OS Therapies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OST-HER2 | Osteosarcoma (HER2+) | Phase 1 |
| OST-tADC Platform | Various Solid Tumors | Pre-clinical |
Leadership Team at OS Therapies
PR
Paul Romness
Chair, Chief Executive Officer, President
RP
Robert Petit
Chief Medical & Scientific Officer, Founding Scientist (OST-HER2)
GC
Gerald Commisiong
Chief Business Officer
JD
Jack Doll
Chief of Staff
CA
Chris Acevedo
Chief Financial Officer (CFO)